Format

Send to

Choose Destination
See comment in PubMed Commons below
Gastroenterol Clin North Am. 2010 Sep;39(3):559-99. doi: 10.1016/j.gtc.2010.08.011.

Clinical pharmacology of 5-ASA compounds in inflammatory bowel disease.

Author information

1
University of Pennsylvania School of Medicine, Suite 100, Stemmler Hall, 3450 Hamilton Walk, Philadelphia, PA 19104, USA.

Abstract

Mesalamine has been the first-line of therapy in patients with inflammatory bowel disease (IBD) since the 1960s. This article serves as a review of the different 5-aminosalicylic acid compounds, release formulations, use and dosing in the treatment of IBD, in particular ulcerative colitis.

PMID:
20951918
DOI:
10.1016/j.gtc.2010.08.011
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center